Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIC002 vaccine for smoking cessation
2007-006741-40Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in nicotine dependence comparing NIC002 vaccine with Placebo (2 arms). Primary endpoint: Continuous abstinence from smoking (weeks 8–12). Started Apr 2008; status: completed.
02
Drugs
NIC002
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on 2007-006741-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006741-40.